TY - JOUR
T1 - Inhibition of FOXP3/NFAT interaction enhances T cell function after TCR stimulation
AU - Lozano, Teresa
AU - Villanueva, Lorea
AU - Durántez, Maika
AU - Gorraiz, Marta
AU - Ruiz, Marta
AU - Belsúe, Virginia
AU - Riezu-Boj, José I.
AU - Hervás-Stubbs, Sandra
AU - Oyarzábal, Julen
AU - Bandukwala, Hozefa
AU - Lourenço, Ana R.
AU - Coffer, Paul J.
AU - Sarobe, Pablo
AU - Prieto, Jesús
AU - Casares, Noelia
AU - Lasarte, Juan J.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Regulatory T cell (Treg) activity is modulated by a cooperative complex between the transcription factor NFAT and FOXP3, a lineage specification factor for Tregs. FOXP3/NFAT interaction is required to repress expression of IL-2, upregulate expression of the Treg markers CTLA4 and CD25, and confer suppressor function to Tregs. However, FOXP3 is expressed transiently in conventional CD4+ T cells upon TCR stimulation and may lead to T cell hyporesponsiveness. We found that a short synthetic peptide able to inhibit FOXP3/NFAT interaction impaired suppressor activity of conventional Tregs in vitro. Specific inhibition of FOXP3/NFAT interaction with this inhibitory peptide revealed that FOXP3 downregulates NFAT-driven promoter activity of CD40L and IL-17. Inhibition of FOXP3/NFAT interaction upregulated CD40L expression on effector T cells and enhanced T cell proliferation and IL-2, IFN-γ, IL-6, or IL-17 production in response to TCR stimulation. The inhibitory peptide impaired effector T cell conversion into induced Tregs in the presence of TGF-β. Moreover, in vivo peptide administration showed antitumor efficacy in mice bearing Hepa129 or TC1 tumor cells when combined with sorafenib or with an antitumor vaccine, respectively. Our results suggest that inhibition of NFAT/FOXP3 interaction might improve antitumor immunotherapies.
AB - Regulatory T cell (Treg) activity is modulated by a cooperative complex between the transcription factor NFAT and FOXP3, a lineage specification factor for Tregs. FOXP3/NFAT interaction is required to repress expression of IL-2, upregulate expression of the Treg markers CTLA4 and CD25, and confer suppressor function to Tregs. However, FOXP3 is expressed transiently in conventional CD4+ T cells upon TCR stimulation and may lead to T cell hyporesponsiveness. We found that a short synthetic peptide able to inhibit FOXP3/NFAT interaction impaired suppressor activity of conventional Tregs in vitro. Specific inhibition of FOXP3/NFAT interaction with this inhibitory peptide revealed that FOXP3 downregulates NFAT-driven promoter activity of CD40L and IL-17. Inhibition of FOXP3/NFAT interaction upregulated CD40L expression on effector T cells and enhanced T cell proliferation and IL-2, IFN-γ, IL-6, or IL-17 production in response to TCR stimulation. The inhibitory peptide impaired effector T cell conversion into induced Tregs in the presence of TGF-β. Moreover, in vivo peptide administration showed antitumor efficacy in mice bearing Hepa129 or TC1 tumor cells when combined with sorafenib or with an antitumor vaccine, respectively. Our results suggest that inhibition of NFAT/FOXP3 interaction might improve antitumor immunotherapies.
UR - http://www.scopus.com/inward/record.url?scp=84942456054&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1402997
DO - 10.4049/jimmunol.1402997
M3 - Article
C2 - 26324768
AN - SCOPUS:84942456054
SN - 0022-1767
VL - 195
SP - 3180
EP - 3189
JO - Journal of Immunology
JF - Journal of Immunology
IS - 7
ER -